What is Imagene AI?
Imagene AI is at the forefront of personalized medicine, specializing in AI-driven molecular testing for cancer. By analyzing a patient's histological data, the company aims to unlock precise, individualized therapeutic strategies. This focus on leveraging advanced artificial intelligence for cancer diagnostics positions Imagene AI as a key player in the rapidly evolving field of oncology and precision health.
How much funding has Imagene AI raised?
Imagene AI has raised a total of $44.5M across 3 funding rounds:
Series A
$18.5M
Angel/Seed
$3M
Series B
$23M
Series A (2022): $18.5M with participation from Dr. David Agus, Eyal Gura, and Larry Ellison
Angel/Seed (2022): $3M led by Blumberg Capital Partners
Series B (2025): $23M supported by Larry Ellison and Aguras Pathology Investments
Key Investors in Imagene AI
Larry Ellison
Larry Ellison is a prominent figure in the tech industry, known for his significant investments in innovative companies, particularly those with a focus on disruptive technologies and healthcare advancements.
Aguras Pathology Investments
Aguras Pathology Investments appears to be a strategic backer focused on advancing diagnostic capabilities within the pathology sector, likely seeking to capitalize on AI-driven innovations.
Blumberg Capital Partners
Blumberg Capital Partners is an early-stage venture capital firm that invests in technology companies, with a known interest in disruptive innovations that can reshape industries.
What's next for Imagene AI?
The recent enterprise-level funding signifies a pivotal growth phase for Imagene AI. This capital infusion is expected to accelerate the company's research and development efforts, enhance its AI platform's capabilities, and expand its market reach. With a clear trajectory from seed-stage development to significant scaling, Imagene AI is poised to further solidify its position in the competitive biotech landscape, driving innovation in cancer treatment pathways.
See full Imagene AI company page
